BIOTEST AG VZ O.N. overview

EQS-Ad-hoc: Biotest AG / Key word(s): Delisting Biotest AG: Delisting agreement and announced delisting tender offer 31-March-2025 / 08:40 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. Ad-hoc RELEASE Announcement according to Article 17 European Market Abuse Regulation (MAR) Biotest AG: Delisting agreement and announced...

EQS-News: Biotest AG / Key word(s): Annual Report Biotest AG increases sales by 6% in financial year 2024 31.03.2025 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest AG increases sales by 6% in financial year 2024 EBIT guidance of € 94.5 million at the upper end of the forecast range achieved Marketing authorization application for fibrinogen submitted in key European markets and to the US Food and Drug Administration (FDA) Approval...

EQS-Ad-hoc: Biotest AG / Key word(s): Personnel Biotest AG: CFO Martin Möller to leave Biotest as planned at the end of his contract. Position of CFO to be filled in the near future. 06-March-2025 / 09:01 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. Ad hoc NOTICE Notification pursuant to Art. 17 EU Market Abuse...

EQS-Ad-hoc: Biotest AG / Key word(s): Annual Results Biotest AG publishes preliminary business figures - 2024 forecasts partially exceeded 26-Feb-2025 / 18:22 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. Ad-hoc RELEASE Announcement according to Article 17 European Market Abuse Regulation (MAR) Biotest publishes...

EQS-News: Biotest AG / Key word(s): Regulatory Admission Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA) 09.01.2025 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA) Biotest's fibrinogen aims to fulfill a high unmet medical need...

EQS-News: Biotest AG / Key word(s): Miscellaneous Minister of Economic Affairs Mansoori and Lord Mayor Benz visit Biotest's plasma center in Darmstadt and call for plasma donations 15.11.2024 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Minister of Economic Affairs Mansoori and Lord Mayor Benz visit Biotest's plasma center in Darmstadt and call for plasma donations Plasma donation centers in Europe to secure the long-term supply of plasma...

EQS-News: Biotest AG / Key word(s): 9 Month figures Biotest increases revenues in the first 9 months by 4.5% to Euro 523 million 14.11.2024 / 10:14 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest increases revenues in the first 9 months by 4.5% to Euro 523 million Product sales and toll manufacturing increased by 13,7% to € 414 million, in part thanks to the growth of Yimmugo ® Adjusted EBIT was maintained at previous year's level as...

EQS-Ad-hoc: Biotest AG / Key word(s): Change in Forecast Biotest AG: Biotest corrects forecast for revenue, cash flow and ROCE – EBIT guidance unchanged 14-Nov-2024 / 08:56 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Ad hoc NOTICE Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR) Biotest corrects...